COVID-19 antibodies on trial.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 33087898.
- Also identified by DOI 10.1038/s41587-020-0732-8 and PMC identifier 7576980.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
With the first readouts of trials of antibodies against COVID-19 appearing and others coming thick and fast, <i>Nature Biotechnology</i> asked a group of experts to comment on the challenges and timelines for these products.
Medical subject headings
- Antibodies
- Coronavirus Infections
- Pandemics
- Pneumonia, Viral